|
|
|
Diarrhea | 53% | 12% |
Nausea/Vomiting | 26% | 8% |
Flatulence | 12% | 6% |
Asthenia | 9% | 6% |
Indigestion | 7% | 4% |
Abdominal Discomfort | 6% | 5% |
Headache | 6% | 5% |
|
|
|
Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride oral solution may increase the risk for lactic acidosis. |
|
Consider more frequent monitoring of these patients. |
|
Topiramate, zonisamide, acetazolamide or dichlorphenamide. |
|
|
|
Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/ multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis |
|
Consider the benefits and risks of concomitant use with metformin hydrochloride oral solution. |
|
Ranolazine, vandetanib, dolutegravir, and cimetidine. |
|
|
|
Alcohol is known to potentiate the effect of metformin on lactate metabolism. |
|
Warn patients against excessive alcohol intake while receiving metformin hydrochloride oral solution. |
|
|
|
Co-administration of metformin hydrochloride oral solution with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia. |
|
Patients receiving an insulin secretagogue or insulin may require lower doses of the insulin secretagogue or insulin. |
|
|
|
Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. |
|
When such drugs are administered to a patient receiving metformin hydrochloride oral solution, observe the patient closely for loss of blood glucose control. When such drugs are withdrawn from a patient receiving metformin hydrochloride oral solution, observe the patient closely for hypoglycemia. |
|
Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. |
|
|
|
|
|
|||
|
1,540.1 ± 451.1 | 9,069.6 ± 2,593.6 | 2.2 ± 0.5 |
|
1,885.1 ± 498.5 | 11,100.1 ± 2,733.1 | 2.5 ± 0.6 |
|
81.2 (76.3 to 86.4) |
81.2 (76.9 to 85.6) |
- |
|
|||
|
1,235.3 ± 177.7 | 8,950.1 ± 1,381.2 | 4.1 ± 0.8 |
|
1,361 ± 298.8 | 9,307.7 ± 1,839.8 | 3.7 ± 0.8 |
|
91.8 (87.4 to 96.5) |
97.0 (92.9 to 101.2) |
- |
|
|
|
|
|
1,641.5 ± 551.8 | 9,982.9 ± 2,544.5 | 2.5 ± 0.9 |
|
1,525.8 ± 396.7 | 11,542.0 ± 2,947.5 | 3.9 ± 0.6 |
|
1,432.5 ± 346.8 | 11,184.5 ± 2,446.1 | 3.9 ± 0.8 |
|
94.6 (84.0 to 106.5) |
115.6 (103.6 to 128.9) |
- |
|
89.4 (79.4 to 100.6) |
112.6 (100.9 to 125.6) |
- |
|
105.8 (94.0 to 119.2) |
102.7 (92.0 to 114.6) |
- |
|
|
|
|
|
|||
500 mg single dose (24) | 1.03 (± 0.33) | 2.75 (±0.81) | 600 (±132) |
850 mg single dose (74) |
1.60 (±0.38) | 2.64 (±0.82) | 552 (±139) |
850 mg three times daily for 19 doses¶ (9) | 2.01 (±0.42) | 1.79 (±0.94) | 642 (±173) |
|
|||
850 mg single dose (23) | 1.48 (±0.5) | 3.32 (±1.08) | 491 (±138) |
850 mg three times daily for 19 doses |
1.90 (±0.62) | 2.01 (±1.22) | 550 (±160) |
|
|||
850 mg single dose (12) | 2.45 (±0.70) | 2.71 (±1.05) | 412 (±98) |
|
|||
|
|||
|
1.86 (±0.52) | 3.20 (±0.45) | 384 (±122) |
|
4.12 (±1.83) | 3.75 (±0.50) | 108 (±57) |
|
3.93 (±0.92) | 4.01 (±1.10) | 130 (±90) |
|
|
|
|
||
|
|
||||
|
|||||
Glyburide | 5 mg | 850 mg | metformin | 0.91 |
0.93‡ |
Furosemide | 40 mg | 850 mg | metformin | 1.09‡ | 1.22‡ |
Nifedipine | 10 mg | 850 mg | metformin | 1.16 | 1.21 |
Propranolol | 40 mg | 850 mg | metformin | 0.90 | 0.94 |
Ibuprofen | 400 mg | 850 mg | metformin | 1.05‡ | 1.07‡ |
|
|||||
Cimetidine | 400 mg | 850 mg | metformin | 1.40 | 1.61 |
|
|||||
Topiramate | 100 mg |
500 mg§ | metformin | 1.25§ | 1.17 |
|
|
|
|
||
|
|
||||
|
|||||
Glyburide | 5 mg | 850 mg | glyburide | 0.78 |
0.63 |
Furosemide | 40 mg | 850 mg | furosemide | 0.87 | 0.69 |
Nifedipine | 10 mg | 850 mg | nifedipine | 1.10 |
1.08 |
Propranolol | 40 mg | 850 mg | propranolol | 1.01§ | 1.02 |
Ibuprofen | 400 mg | 850 mg | ibuprofen | 0.97 |
1.01¶ |
Cimetidine | 400 mg | 850 mg | cimetidine | 0.95§ | 1.01 |
|
|
|
|
|
|||
Baseline | 241.5 | 237.7 | NS |
Change at FINAL VISIT | -53.0 | 6.3 | 0.001 |
|
|||
Baseline | 8.4 | 8.2 | NS* |
Change at FINAL VISIT | -1.4 | 0.4 | 0.001 |
|
|
|
|
|||
|
|
|
||||
|
||||||
Baseline | 250.5 | 247.5 | 253.9 | NS |
NS* | NS* |
Change at FINAL VISIT | -63.5 | 13.7 | -0.9 | 0.001 | 0.001 | 0.025 |
|
||||||
Baseline | 8.8 | 8.5 | 8.9 | NS* | NS* | 0.007 |
Change at FINAL VISIT | -1.7 | 0.2 | -0.4 | 0.001 | 0.001 | 0.001 |
|
|
|
|
|
|
|
|
Baseline | 162.4 | 192.3 | |
Change at FINAL VISIT | -42.9 | 21.4 | <0.001 |
|
|
|
|
|
Strawberry | clear, colorless liquid |
Unit-Dose Cups (Institutional use) |
5 mL (500 mg) fill, case of 5 trays x 10s |
52817-820-50 |
8.5 mL (850 mg) fill, case of 5 trays x 10s |
52817-821-50 | |||
10 mL (1,000 mg) fill, case of 5 trays x 10s |
52817-822-50 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|